Foreign-Exchange Provisioning Masks Indian Pharma Health
This article was originally published in PharmAsia News
Executive Summary
Stock analysts see a rosy future for India's pharmaceutical companies that saw an overall 23 percent increase in net sales during the recent quarter. Analysts see an even better quarter following as long as the rupee does not fluctuate greatly with the U.S. dollar. The leading companies suffered a hit by having to provision for foreign-exchange losses, causing some of the firms to post losses within India for the quarter. Analysts also note Indian drug makers are expected to weather a global economic slowdown because drugs are considered essential products. (Click here for more
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.